Wire Stories
Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-? Bispecific Antibody for Patients with Advanced Solid Tumors
SHANGHAI & SUZHOU, China & GERMANTOWN, Md.–(BUSINESS WIRE)–Elpiscience Biopharmaceuticals, Inc. (�Elpiscience�), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit...